Osmosis Investment Management UK Ltd Sells 13,404 Shares of Amgen Inc. $AMGN

Osmosis Investment Management UK Ltd lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 29.1% during the second quarter, Holdings Channel.com reports. The firm owned 32,649 shares of the medical research company’s stock after selling 13,404 shares during the quarter. Osmosis Investment Management UK Ltd’s holdings in Amgen were worth $11,823,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Roman Butler Fullerton & Co. raised its position in shares of Amgen by 1.4% in the 2nd quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock valued at $705,000 after purchasing an additional 27 shares during the last quarter. High Note Wealth LLC increased its stake in shares of Amgen by 5.8% in the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after acquiring an additional 28 shares during the period. TAGStone Capital Inc. raised its holdings in shares of Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after purchasing an additional 28 shares during the last quarter. Verus Capital Partners LLC raised its position in Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares in the last quarter. Finally, Destination Wealth Management raised its position in Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 6,222 shares of company stock worth $2,540,926. Corporate insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on AMGN shares. TD Cowen increased their price target on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Mizuho increased their target price on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Argus lifted their price objective on Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. Finally, Bank of America boosted their price objective on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $380.43.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
• Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
• Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
• Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
• Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $439.33 on Monday. The company has a market capitalization of $237.51 billion, a P/E ratio of 27.30, a P/E/G ratio of 3.17 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The company has a 50 day simple moving average of $379.03 and a 200-day simple moving average of $362.07. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $443.20.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts predict that Amgen Inc. will post 22.92 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.